These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5974192)

  • 1. [Clinical study on the effects of L-ornithine-L-aspartate on liver dysfunction].
    Kosozu K
    Iryo; 1966 Apr; 20(4):339-46. PubMed ID: 5974192
    [No Abstract]   [Full Text] [Related]  

  • 2. [Further clinical experiences with ornithine aspartate in liver diseases].
    Wotzka R; Weber D
    Ther Ggw; 1972 Mar; 111(3):400-12. PubMed ID: 5024593
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the therapy of liver diseases with ornithine aspartate].
    Melzer H; Weber D; Wotzka R
    Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
    Seki S
    Iryo; 1966 Apr; 20(4):354-63. PubMed ID: 5974194
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experiences with ornithine-aspartate in liver diseases].
    Aschke J
    Med Welt; 1969 Mar; 12():657-62. PubMed ID: 5767441
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of treatment with nucleotides and aspartic acid in chronic liver diseases].
    Iencica R
    Med Interna (Bucur); 1972 Dec; 24(12):1449-53. PubMed ID: 4655566
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinico-experimental findings on the use of a new liver protective agent].
    Catalfamo G; Melotti G; Soffritti E
    Minerva Med; 1967 Apr; 58(34 Suppl):1605-12. PubMed ID: 4226047
    [No Abstract]   [Full Text] [Related]  

  • 8. [Our clinical experience with ornithine aspartate].
    Szirmai E
    Minerva Med; 1971 Jun; 62(47):2376-82. PubMed ID: 5087700
    [No Abstract]   [Full Text] [Related]  

  • 9. [Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].
    Henglein-Ottermann D
    Ther Ggw; 1976 Sep; 115(9):1504-18. PubMed ID: 968783
    [No Abstract]   [Full Text] [Related]  

  • 10. [Betaine aspartate in the hepato-digestive domain].
    Cachin M; Pergola F
    Sem Ther; 1966 Oct; 42(8):423-4. PubMed ID: 5994378
    [No Abstract]   [Full Text] [Related]  

  • 11. [Personal experiences in the treatment of internal diseases with ornithine aspartate].
    Perinović M; Robović Z; Grujić M; Ljubojević S
    Med Arh; 1969; 23(3):29-32. PubMed ID: 5200044
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical experiences with heparmez].
    Baumann M
    Z Allgemeinmed; 1970 Jun; 46(17):895-900. PubMed ID: 5509064
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical trial of alpha ornithine ketoglutarate].
    Linquette M; Fossati P; Hubschman B
    Lille Med; 1969 Apr; 14():Suppl 3:512-5. PubMed ID: 5376446
    [No Abstract]   [Full Text] [Related]  

  • 14. Experimental liver damage in potassium depletion, inhibited by L-ornithine-L-aspartate.
    Raab WP
    Arzneimittelforschung; 1971 Oct; 21(10):1620-1. PubMed ID: 5171899
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
    Chen MF; Li RC; Chen CH; Gao XC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of L-ornithin-L-aspartate on toxic kidney disorders similar to nephrosis].
    Raab W
    Dtsch Med J; 1972 Dec; 23(12):705-8. PubMed ID: 4659004
    [No Abstract]   [Full Text] [Related]  

  • 17. [Protection of the liver and liver therapy with Hepamerz].
    Heynen U
    Z Allgemeinmed; 1970 Jan; 46(2):87-8. PubMed ID: 5439291
    [No Abstract]   [Full Text] [Related]  

  • 18. [A new multienzyme complex. Clinical trial in hepatitis and cirrhosis].
    Ribet A; Vidal JL
    Nouv Presse Med; 1972 Nov; 1(42):2843-4. PubMed ID: 4663747
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
    Hunold W
    Z Allgemeinmed; 1973 Apr; 49(10):469-72. PubMed ID: 4580434
    [No Abstract]   [Full Text] [Related]  

  • 20. Kaliopenic nephrosis: protective action of L-ornithine-L-aspartate.
    Raab WP
    Clin Chim Acta; 1972 Jun; 39(1):239-42. PubMed ID: 5038753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.